Murakami A, Koga S, Maeta M
First Department of Surgery, Tottori University School of Medicine, Yonago, Japan.
Oncology. 1988;45(3):236-41. doi: 10.1159/000226568.
Thermochemosensitivity was examined in vitro by a human tumor clonogenic assay (HTCA) using specimens obtained surgically from 43 patients with colorectal cancer. We found that the percentages of patients whose cells showed higher sensitivity (greater than 70% inhibition of colony formation) to hyperthermia alone were 29.6 and 55.6% at 42 and 43 degrees C each for 1 h, respectively. Similarly, percentages of patients whose cells were sensitive to drugs alone were 13.8, 24.1 and 48.3%, for cis-diamminedichloroplatinum(II), 5-fluorouracil and mitomycin C, respectively. These sensitivities were augmented when hyperthermia was combined with administration of anticancer agents. Even in tumor cells that were insensitive to anticancer drugs alone or to hyperthermia alone, sensitivity was enhanced when administration of drugs was combined with hyperthermia. Our results demonstrate that HTCA of tumor cells, obtained from suitable patients, may be useful as a predictive test for application of thermotherapy and for individualization of chemotherapy.
利用从43例结肠癌患者手术获取的标本,通过人肿瘤克隆形成试验(HTCA)在体外检测热化学敏感性。我们发现,细胞对单纯热疗显示出较高敏感性(集落形成抑制率大于70%)的患者百分比,在42℃和43℃下各1小时分别为29.6%和55.6%。同样,细胞对单纯药物敏感的患者百分比,顺二氯二氨铂(II)、5-氟尿嘧啶和丝裂霉素C分别为13.8%、24.1%和48.3%。当热疗与抗癌药物联合使用时,这些敏感性会增强。即使在对单纯抗癌药物或单纯热疗不敏感的肿瘤细胞中,药物给药与热疗联合时敏感性也会增强。我们的结果表明,从合适患者获取的肿瘤细胞HTCA,可能作为热疗应用和化疗个体化的预测试验有用。